Celsion Announces Promising Phase I ThermoDox(R) Results In Breast Cancer Presented A

[News]

Celsion Corporation (NASDAQ: CLSN) today announced that promising Phase I clinical results evaluating ThermoDox for the treatment of recurrent chest wall (RCW) breast cancer were presented by Duke University investigators on Sunday, April 5 at the 2009 Annual Meeting of the Society for Thermal Medicine (STM) in Tucson, Arizona.

More... (http://www.medicalnewstoday.com/articles/145447.php)